Technology area
Bioinformatics
449 funded awards, $303.0M total, FY2023-FY2025.
Where the money sat, by Institute / Center
IC funding decisions are set by portfolio priorities, NOFO scope, and program-officer judgment. These are funded records, not predictions of future funding.
| IC | Name | Records | Median award |
|---|---|---|---|
| GM (NIGMS) | National Institute of General Medical Sciences | 109 | $731,568 |
| CA (NCI) | National Cancer Institute | 74 | $678,817 |
| AI (NIAID) | National Institute of Allergy and Infectious Diseases | 53 | $843,964 |
| HG (NHGRI) | National Human Genome Research Institute | 50 | $406,895 |
| AG (NIA) | National Institute on Aging | 40 | $865,892 |
| DK (NIDDK) | National Institute of Diabetes and Digestive and Kidney Diseases | 26 | $498,516 |
| TR (NCATS) | National Center for Advancing Translational Sciences | 20 | $346,624 |
| HL (NHLBI) | National Heart Lung and Blood Institute | 16 | $303,111 |
| NS (NINDS) | National Institute of Neurological Disorders and Stroke | 15 | $459,525 |
| MH (NIMH) | National Institute of Mental Health | 12 | $1,231,991 |
| EY (NEI) | National Eye Institute | 6 | $550,175 |
| AT (NCCIH) | National Center for Complementary and Integrative Health | 5 | $302,392 |
| ES (NIEHS) | National Institute of Environmental Health Sciences | 5 | $306,374 |
| OD | NIH Office of the Director | 4 | $1,009,093 |
| DA (NIDA) | National Institute on Drug Abuse | 4 | $392,933 |
| DE (NIDCR) | National Institute of Dental and Craniofacial Research | 4 | $933,207 |
| HD (NICHD) | Eunice Kennedy Shriver National Institute of Child Health and Human Development | 2 | $297,008 |
| AA (NIAAA) | National Institute on Alcohol Abuse and Alcoholism | 1 | $322,070 |
| MD (NIMHD) | National Institute on Minority Health and Health Disparities | 1 | $294,450 |
| LM (NLM) | National Library of Medicine | 1 | $349,432 |
| AR (NIAMS) | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 1 | $275,250 |
FOA / NOFO routes
Opportunity number prefixes: PA = Parent Announcement (broad, omnibus, multiple ICs), PAR = Parent with Special Review, PAS = Parent with set-aside funds, RFA = Request for Applications (targeted, single-IC, fixed budget). Status unknown means the pipeline has not verified whether the FOA is currently posting awards; the SBIR omnibus has been in reauthorization gap during this window. See the glossary for full definitions.
| Opportunity | Status | Records |
|---|---|---|
| PA-22-176 | unknown | 107 |
| PA-23-230 | unknown | 84 |
| PA-21-259 | unknown | 61 |
| PA-24-245 | unknown | 39 |
| PAS-22-196 | unknown | 22 |
| PA-23-232 | unknown | 17 |
| PA-20-260 | unknown | 16 |
| PA-24-247 | unknown | 14 |
| PA-22-178 | unknown | 13 |
| PA-20-047 | unknown | 11 |
| PA-20-272 | unknown | 5 |
| PA-21-262 | unknown | 5 |
| PA-22-177 | unknown | 4 |
| RFA-CA-23-035 | unknown | 4 |
| PA-25-212 | unknown | 3 |
| RFA-HG-21-008 | unknown | 3 |
| PAS-19-316 | unknown | 3 |
| PAR-21-247 | unknown | 3 |
| PA-21-345 | unknown | 3 |
| RFA-CA-22-025 | unknown | 2 |
| PA-23-233 | unknown | 2 |
| RFA-CA-22-017 | unknown | 2 |
| RFA-CA-21-001 | unknown | 2 |
| RFA-ES-20-008 | unknown | 2 |
| PA-19-272 | unknown | 2 |
| PAS-19-317 | unknown | 2 |
| PAR-21-225 | unknown | 1 |
| RFA-DA-24-038 | unknown | 1 |
| RFA-MD-24-007 | unknown | 1 |
| RFA-DA-25-053 | unknown | 1 |
| RFA-DA-23-021 | unknown | 1 |
| PAR-24-131 | expired | 1 |
| PA-24-248 | unknown | 1 |
| PAS-22-197 | unknown | 1 |
| PA-24-246 | unknown | 1 |
| PA-20-025 | unknown | 1 |
| PAR-23-213 | unknown | 1 |
| RFA-MD-23-002 | unknown | 1 |
| RFA-DA-19-020 | unknown | 1 |
| RFA-DK-21-012 | unknown | 1 |
| PA-18-574 | unknown | 1 |
| PA-20-265 | unknown | 1 |
| PA-21-260 | unknown | 1 |
| RFA-NS-23-006 | unknown | 1 |
Comparable funded projects
| ApplID | FY | IC | Title | Organization | Amount |
|---|---|---|---|---|---|
| 10825409 | 2025 | OD | Tools and Methods for Producing High Quality Functional Protein Microarrays for Biomarker Discovery | SPOC PROTEOMICS INC. | $1,370,834 |
| 10907583 | 2025 | CA | Development of a Universal Assay for Minimal Residual Disease in Acute Myeloid Leukemia using Duplex Sequencing | TWINSTRAND BIOSCIENCES, INC. | $1,985,831 |
| 10994631 | 2025 | GM | Research and cloud deployment of enhanced sampling methods in MovableType | QUANTUMBIO, INC. | $654,406 |
| 11005406 | 2025 | AI | Development of a Rapid Phenotypic Pyrazinamide Susceptibility Testing for Mycobacterium tuberculosis Using Well-Standardized Protocol | PZA INNOVATION LLC | $843,964 |
| 11008553 | 2025 | GM | Improved Methods and Commercialization of a Multimodal Vibrating Sharp-Edge Spray Ionization Source | INVIBRAGEN INC. | $1,147,352 |
| 11014847 | 2025 | GM | Combinatorial pipeline for discovery of anti-GPCR Nanobodies | BIOCOGNON LLC | $303,024 |
| 11032992 | 2025 | DA | Advancing Nr4a1 as a novel target in cocaine use disorder. | RAFIAS LLC | $405,230 |
| 11039937 | 2025 | AI | Development of ultra-efficient antibodies for single cell mapping applications | EPICYPHER, INC. | $1,004,302 |
Limitations
- RePORTER includes funded projects only, not unfunded applications.
- Panel sidebar reflects panels that have appeared on funded records, not future assignment.
- FOA-route status reflects verification at the timestamp shown.
- Tag 'bioinformatics' is a Cada controlled-vocabulary tag; see methodology for definitions.
Pattern read
Bioinformatics is anchored by NIGMS (109 records) and NCI (74), the two ICs that have historically funded computational-method development and oncology data analytics. NIAID at 53 follows, mostly genomic surveillance and sequence-analysis tools. The tag captures a higher proportion of Phase II awards than most (255 R44 vs 129 R43), which reflects the fact that bioinformatics work tends to mature into productizable platforms once an algorithm has been validated. Median award is $569K, on the higher end. Recipient concentration is roughly 9% in the top three, which is higher than most therapeutic tags; a smaller pool of specialized firms shows up repeatedly. STTR (R41) participation is modest at 46 but real, and the academic-spinout pattern still drives a slice of the work.
Fit indicators
Watchouts